Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Analyst Ratings
Moderate Buy
10 Buy
7 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRK Stock 12 Month Forecast
Average Price Target
$102.27
▲(21.78%Upside)
| Highest Price Target$141.00 | Average Price Target$102.27 | Lowest Price Target$82.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$94
Buy
11.93%
Upside
Reiterated
07/23/25
Bank of America Securities
$99
Buy
17.89%
Upside
Reiterated
07/23/25
Leerink Partners
$115→$92
Buy
9.55%
Upside
Reiterated
07/18/25
Merck & Company: Buy Rating Backed by Growth Prospects in Cardiopulmonary and Infectious Disease FranchisesWe believe several upcoming readouts could meaningfully expand Merck’s long-term revenue potential and reinvigorate interest in the stock, including enlicitide’s (oral PCSK9 inhibitor) trio of Ph3 lipid-lowering trials (likely in November), results from Winrevair in combined pre- and post-capillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF) (Ph2 CADENCE 3Q25), and Keytruda + Welireg (HIF-2α inhibitor) in adjuvant renal cell carcinoma (RCC) (Ph3 LITESPARK-022 4Q26). The later two trials are high-risk/high-reward where success could drive outsized excitement. See within for further discussion of these programs.
BMO Capital
$82
Hold
-2.36%
Downside
Reiterated
07/17/25
Wells Fargo
$97
Hold
15.50%
Upside
Reiterated
07/17/25
Guggenheim
$108
Buy
28.60%
Upside
Reiterated
07/13/25
UBS
$105
Buy
25.03%
Upside
Reiterated
07/10/25
Jefferies
$138→$141
Buy
67.90%
Upside
Reiterated
07/10/25
Morgan Stanley
$99→$98
Hold
16.69%
Upside
Reiterated
07/10/25
Cantor Fitzgerald
$85→$83
Hold
-1.17%
Downside
Reiterated
07/09/25
Goldman Sachs
$99
Buy
17.89%
Upside
Reiterated
07/09/25
Bernstein
―
Hold
―
Reiterated
07/08/25
J.P. Morgan
$130
Buy
54.80%
Upside
Reiterated
07/07/25
Berenberg Bank
$100
Buy
19.08%
Upside
Reiterated
07/01/25
TD Cowen
$100
Hold
19.08%
Upside
Reiterated
06/26/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$94
Buy
11.93%
Upside
Reiterated
07/23/25
Bank of America Securities
$99
Buy
17.89%
Upside
Reiterated
07/23/25
Leerink Partners
$115→$92
Buy
9.55%
Upside
Reiterated
07/18/25
Merck & Company: Buy Rating Backed by Growth Prospects in Cardiopulmonary and Infectious Disease FranchisesWe believe several upcoming readouts could meaningfully expand Merck’s long-term revenue potential and reinvigorate interest in the stock, including enlicitide’s (oral PCSK9 inhibitor) trio of Ph3 lipid-lowering trials (likely in November), results from Winrevair in combined pre- and post-capillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF) (Ph2 CADENCE 3Q25), and Keytruda + Welireg (HIF-2α inhibitor) in adjuvant renal cell carcinoma (RCC) (Ph3 LITESPARK-022 4Q26). The later two trials are high-risk/high-reward where success could drive outsized excitement. See within for further discussion of these programs.
BMO Capital
$82
Hold
-2.36%
Downside
Reiterated
07/17/25
Wells Fargo
$97
Hold
15.50%
Upside
Reiterated
07/17/25
Guggenheim
$108
Buy
28.60%
Upside
Reiterated
07/13/25
UBS
$105
Buy
25.03%
Upside
Reiterated
07/10/25
Jefferies
$138→$141
Buy
67.90%
Upside
Reiterated
07/10/25
Morgan Stanley
$99→$98
Hold
16.69%
Upside
Reiterated
07/10/25
Cantor Fitzgerald
$85→$83
Hold
-1.17%
Downside
Reiterated
07/09/25
Goldman Sachs
$99
Buy
17.89%
Upside
Reiterated
07/09/25
Bernstein
―
Hold
―
Reiterated
07/08/25
J.P. Morgan
$130
Buy
54.80%
Upside
Reiterated
07/07/25
Berenberg Bank
$100
Buy
19.08%
Upside
Reiterated
07/01/25
TD Cowen
$100
Hold
19.08%
Upside
Reiterated
06/26/25
Best Analysts Covering Merck & Company
1 Month
xxx
Success Rate
10/14 ratings generated profit
Average Return
+1.41%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +1.41% per trade.
3 Months
xxx
Success Rate
9/14 ratings generated profit
Average Return
+1.34%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +1.34% per trade.
1 Year
Success Rate
26/48 ratings generated profit
Average Return
+4.98%
reiterated a buy rating 7 days ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +4.98% per trade.
2 Years
xxx
Success Rate
13/18 ratings generated profit
Average Return
+10.28%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 72.22% of your transactions generating a profit, with an average return of +10.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRK Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
2
2
2
3
4
Buy
25
28
21
24
20
Hold
17
19
15
26
23
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
44
49
38
54
48
Each month's total comprises the sum of three months' worth of ratings.
MRK Financial Forecast
MRK Stock Forecast FAQ
What is MRK’s average 12-month price target, according to analysts?
Based on analyst ratings, Merck & Company’s 12-month average price target is 102.27.
What is MRK’s upside potential, based on the analysts’ average price target?
Merck & Company has 21.78% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRK a Buy, Sell or Hold?
Merck & Company has a consensus rating of Moderate Buy which is based on 10 buy ratings, 7 hold ratings and 0 sell ratings.
What is Merck & Company’s price target?
The average price target for Merck & Company is 102.27. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $141.00 ,the lowest forecast is $82.00. The average price target represents 21.78% Increase from the current price of $83.98.
The highest analyst price target is $141.00 ,the lowest forecast is $82.00. The average price target represents 21.78% Increase from the current price of $83.98.
What do analysts say about Merck & Company?
Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of MRK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.